When: $57.86 with confirmed 200 SMA hold (2-3 sessions, RSI curling up, MACD histogram no longer expanding)

Then: Add half position

When: $60 bounce with 10 EMA reclaim

Then: Add second half position

When: $68 retest without confirmation

Then: Trim 20-30%

HOLD

• Q2 EPS of $1.62 represents peak earnings power before Eliquis patent cliff hits; calling it a new baseline is an analytical trap
• 9.7x forward P/E only appears cheap if estimates hold; a 20-30% earnings reset expands multiple to 15-16x
• Arlo-cel is Phase 2 data, not a commercial product; realistic revenue contribution is 2028-2029, not solving the 2026-2028 gap
• Technical setup is precarious: price four cents above 50 SMA, MACD histogram at negative 0.60, $1.15 below 10 EMA, VWMA $2.09 above price
• Entry at $57.86 means absorbing 9.5% drawdown on existing position before initiating
• FCF coverage of 2.5x compresses to 1.8-2.0x post-Loss of Exclusivity given Eliquis is a $12B+ revenue product
• Cytokinetics patent dispute adds discrete legal overhang on cardiovascular franchise
• 10-year Treasury at 2007 highs competes with BMY's 4% yield on risk-adjusted basis
• Recession odds ticked up 6.5 percentage points in one week to 14%
• Arlo-cel regulatory pathway clarity needed within two quarters or reassess entire thesis

→ vs aggressive: Q2 2026 'blowout quarter' framing ignores that $1.62 EPS was earned at peak Eliquis contribution before patent cliff; one quarter does not undo five years of revenue stagnation

→ vs aggressive: Phase 2 arlo-cel success is not equivalent to commercial product; oncology drug development has brutal attrition and realistic timeline is 2028-2029 at earliest

→ vs aggressive: Novartis pause is a relative positioning tailwind in a single indication, not a demand creator or timeline accelerator

→ vs aggressive: Pullback described as 'healthy' and 'orderly' is imprecise; MACD has crossed bearish with expanding histogram and VWMA is $2.09 above price confirming real selling

→ vs aggressive: 200 SMA support analysis in 2020-2021 was during healthier business conditions; not a guarantee in patent cliff environment

→ vs aggressive: 2.5x FCF coverage assumes $13B FCF; a significant portion comes from products facing generic erosion, pushing realistic post-LOE coverage to 1.8-2.0x

→ vs aggressive: Patent cliff funds existing payout, not dividend growth; growth stops, historically pressuring multiples for Aristocrat names

→ vs neutral: Absence of position should not be interpreted as endorsement; sitting unhedged at a critical technical pivot with bearish momentum shift is exposed, not neutral

HOLD existing position with hard stop at $63.69 daily close, tiered entry strategy for new capital (50% at $57.86 with 2-3 session confirmation, remainder at $60 with 10 EMA reclaim), 90-day reassessment trigger, and optional protective puts through FOMC windows

• HOLD decision is correct - operational improvement in H1 2026 is encouraging but Q2 2026 $1.62 EPS should not be anchored as a new baseline
• Arlo-cel is structurally meaningful as first-in-class GPRC5D-directed CAR-T but is a 2028-2029 revenue contributor at earliest - cannot bridge the Eliquis exclusivity cliff starting 2026
• Aggressive analyst's 2.5 to 1 reward-to-risk framing ignores 9.5% additional drawdown required to reach the $57.86 entry from current levels
• Conservative analyst's 200 SMA concern is speculative - major pharma with strong FCF and dividend track records historically hold their 200 SMA even through stress events (BMY held through COVID)
• Beta of 0.227 provides defensive characteristics in elevated recession environment (odds up 6.5 percentage points week-over-week)
• Dividend coverage at 2.5x FCF compressing to 1.8-2.0x post-LOE is defensible - growth stops before the dividend itself is cut
• Position framing as 'exposed' is too aggressive - a $130 billion market cap name with 4% dividend, $13 billion annual FCF, and 0.227 beta is not a high-risk position
• Tighten existing position risk with hard stop at $63.69 (50 SMA) - disqualifier if violated on daily close
• Scale in new capital in two tranches with confirmation requirements rather than binary entry at touch

→ vs aggressive: Q2 2026 $1.62 EPS is not confirmed baseline - one quarter does not establish a new earnings power level given Eliquis is still generating full revenue contribution

→ vs aggressive: Arlo-cel cannot bridge near-term Eliquis cliff - Phase 2 success is not commercial revenue, and timeline mismatch is structural

→ vs aggressive: Reward-to-risk framing treats $57.86 entry trigger as free when 9.5% additional drawdown must be absorbed on existing position first

→ vs conservative: 200 SMA 'may not hold' is speculative - beta of 0.227 and defensive characteristics historically support holding even in challenging environments

→ vs conservative: Dividend at risk framing conflates coverage compression with actual cut - 1.8-2.0x coverage post-LOE is still defensible payout ratio

→ vs conservative: Position described as 'exposed' overstates risk - low-beta, high-FCF, Aristocrat dividend name is not comparable to leveraged biotech risk profile